Table 1.
Patients’ characteristics (n = 450) (%).
| Mean age (range) (years) | 71 (40–84) |
|---|---|
| Sex | |
| Male | 156 (34) |
| Female | 294 (66) |
| Primary site | |
| Colon | 272 (60) |
| Rectum | 178 (40) |
| Initial treatment | |
| Surgery | 371 (82) |
| RCHT + surgery | 68 (15) |
| Systemic therapy | 11 (3) |
| Adjuvant chemotherapy | |
| Yes | 114 (25) |
| No | 324 (72) |
| Unknown | 12 (3) |
| Histology | |
| Adenocarcinoma | 429 (95) |
| Mucinous carcinoma | 21 (5) |
| Initial stage | |
| Stage I | 15 (3) |
| Stage II | 94 (21) |
| Stage III | 186 (41) |
| Stage IV | 127 (28.5) |
| Unknown | 28 (6.5) |
| Tumor mutations (%) | |
| EGFR | 3.3 |
| KRAS | 22.6 |
| NRAS | 3 |
| BRAF | 1.76 |
| MSI | 0.44 |
| Median time to OMD (range) | 23.7 (0–126) |
| Systemic treatment before SABR | |
| Chemotherapy | 249 (55.5) |
| TKI | 4 (0.9) |
| Antiangiogenetic | 32 (7) |
| Target therapy/immunotherapy | 6 (1.3) |
| No | 118 (26.3) |
| Unknown | 41 (9) |
| Type of oligometastases | |
| Synchronous | 106 (23.5) |
| Metachronous | 344 (76.5) |
| RCHT: radiochemotherapy; OMD: oligometastatic disease: SBRT: stereotactic body radiotherapy; TKI: tyrosine-kinases inhibitor | |